Full-Time

AV Production Technician

Updated on 9/10/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$70.9k - $96k/yr

+ Discretionary annual bonus + Stock-based long-term incentives

Thousand Oaks, CA, USA

In Person

Bachelor's, Associate's

Category
Creative Production (1)
Required Skills
SharePoint
Agile
Microsoft Outlook

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A bachelor's degree, or an associate's degree with 4 years of engineering and/or event production experience, or a high school diploma/GED with 6 years of engineering and/or event production experience.
  • Hands-on experience supporting live, hybrid, and virtual event production in a corporate, enterprise, auditorium, broadcast, or similar professional environment.
  • Strong working knowledge of professional audio systems, including microphones, wireless systems, mixers/consoles, digital signal processors, signal flow, gain structure, and live audio troubleshooting.
  • Practical experience with Dante audio, including device setup, routing, patching, monitoring, and troubleshooting.
  • Strong working knowledge of professional video systems, including cameras, switchers, displays, video playback, capture devices, signal routing, and production workflows.
  • Practical experience with NDI video, including NDI software, hardware devices, IP-based video workflows, and troubleshooting.
  • Experience supporting streaming, webcasting, and virtual event platforms.
  • Experience supporting collaboration platforms such as Webex, Microsoft Teams, and Zoom in live or executive-facing environments.
  • Strong troubleshooting skills with the ability to remain composed and effective under pressure.
  • Clear communication with technical and non-technical stakeholders.
  • Strong organizational skills, attention to detail, and the ability to manage multiple priorities in a fast-paced environment.
  • Self-directed and proactive, with the ability to learn new technologies, tools, and production workflows.
Responsibilities
  • Support the end-to-end technical execution of live, hybrid, and virtual events, including meetings, town halls, webcasts, executive events, auditorium productions, and large-scale campus events.
  • Operate, configure, and troubleshoot AV production systems, including audio consoles, video switchers, playback systems, cameras, microphones, encoders, decoders, displays, and control room equipment.
  • Manage and support Dante audio networks, including audio routing, device configuration, signal flow validation, monitoring, and troubleshooting.
  • Manage and support NDI video workflows, including NDI-enabled cameras, encoders/decoders, routing, discovery, software tools, and network-based video transport.
  • Provide technical support for streaming and webcasting platforms, including event setup, testing, monitoring, and live support.
  • Support virtual and hybrid meeting technologies, including Webex, Microsoft Teams, and Zoom, ensuring strong audio/video quality and a smooth user experience.
  • Serve in live production roles as needed, such as Audio Technician, Video Technician, Virtual Meeting Operator, Graphics Operator, Playback Operator, Streaming Technician, or Technical Support.
  • Perform pre-event checks, equipment readiness assessments, signal testing, room validation, and quality control to ensure successful event delivery.
  • Partner with event owners, coordinators, executives, presenters, and technical teams to understand event goals and translate them into effective production plans.
  • Maintain auditoriums and control room systems, including video walls, audio systems, control systems, networked AV devices, and production equipment.
  • Troubleshoot issues during live events and escalate when needed while maintaining a solutions-focused presence.
  • Support continuous improvement of AV production spaces, workflows, documentation, equipment standards, and operational procedures.
  • Coordinate with vendors and internal technical teams for equipment repairs, upgrades, installations, and event-specific production needs.
  • Support internal clients, including senior executives and business-critical stakeholders, with customer service.
Desired Qualifications
  • Experience supporting live events, executive meetings, webcasts, or corporate AV production for large enterprise environments.
  • Experience with Webex Events, Microsoft Teams Live Events/Town Halls, Socio, Kaltura, Zoom Events/Webinars, VizRT, or similar production and streaming technologies.
  • Experience with production switchers such as Analog Way Aquilon or other industry-standard video switching platforms.
  • Experience with video systems such as Lightware, Panasonic PTZ cameras, NDI, Epiphan Pearl 2, Kipro Ultra, Atomos, Perfect Cue Clickers, and Speaker Timers.
  • Experience with audio systems such as Shure, Yamaha CL/QL and DM7 consoles, Biamp, or similar professional audio platforms.
  • Experience supporting Crestron-controlled rooms, auditoriums, video walls, AV-over-IP systems, or enterprise collaboration spaces.
  • Knowledge of Office 365 collaboration tools, Outlook, Teams, SharePoint, Box, or other enterprise productivity platforms.
  • Experience with PC and Mac computers.
  • Familiarity with Agile practices, ticketing systems, or enterprise IT support environments.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
  • Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
  • MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.

What critics are saying

  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
  • FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
  • Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.

What makes Amgen unique

  • Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
  • MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.